Market Overview

UPDATE: Canaccord Genuity Initiates Synergy Pharmaceuticals at Buy on Opportunities

Share:
Related SGYP
The Week Ahead: Earnings, Earnings, And More Earnings
Benzinga's Option Alert Recap From October 5

Canaccord Genuity initiated coverage on Synergy Pharmaceuticals (NASDAQ: SGYP) with a Buy rating and a $7 price target.

Canaccord Genuity commented, "We see clear unmet need for the large proportion of chronic constipation patients non-responsive to current therapies and the smaller proportion that experience severe diarrhea with linaclotide (Linzess). Compared to recently approved Linzess (Forest/Ironwood), plecanatide may have better tolerability, with no diarrhea signal seen in Phase 2a. Data from the Phase 2b/3 trial is due by YE12, and if safety continues to be clean we expect wide use in severe chronic constipation, noting the market for severe idiopathic constipation may be limited."

Synergy Pharmaceuticals closed at $3.67 on Tuesday.

Latest Ratings for SGYP

DateFirmActionFromTo
Sep 2017CitigroupMaintainsSell
Jun 2017Cantor FitzgeraldInitiates Coverage OnOverweight
Apr 2017CitigroupDowngradesNeutralSell

View More Analyst Ratings for SGYP
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (SGYP)

View Comments and Join the Discussion!
Loading...

Partner Center

Loading...